Sickle Cell Innovators Required: Emmaus' Pending Approval Highlights Rare Disease Void
FDA approval is likely for Emmaus' sickle cell drug L-glutamine this summer, representing the first new product for the disease since 1998 – a decision FDA advisory committee panelists hope will spur more innovation.
